Alvarez-Mon M A, García-Montero Cielo, Fraile-Martinez Oscar, Quintero Javier, Fernandez-Rojo Sonia, Mora Fernando, Gutiérrez-Rojas Luis, Molina-Ruiz Rosa M, Lahera Guillermo, Álvarez-Mon Melchor, Ortega Miguel A
Department of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
Brain Sci. 2023 Feb 15;13(2):333. doi: 10.3390/brainsci13020333.
Major depressive disorder (MDD) is a complex psychiatric disorder that, presented alone or with other comorbidities, requires different adjustments of antidepressant treatments. Some investigations have demonstrated that psychoactive drugs, such as serotonin and norepinephrine reuptake inhibitors (SNRIs), can exert more effective and faster antidepressant effects than other common medications used, such as serotonin selective reuptake inhibitors (SSRIs), although these differences are still controversial. During the last five years, the SNRI duloxetine has shown favorable results in clinical practice for the treatment of MDD, anxiety, and fibromyalgia. Through an online self-completed survey, in the present article, we collected information from 163 psychiatrists regarding the use of duloxetine and its comparison with other psychiatric drugs, concerning psychiatrists' knowledge and experience, as well as patients' preferences, symptoms, and well-being. We discussed and contrasted physicians' reports and the scientific literature, finding satisfactory concordances, and finally concluded that there is agreement regarding the use of duloxetine, not only due to its tolerability and effectiveness but also due to the wide variety of situations in which it can be used (e.g., somatic symptoms in fibromyalgia, diabetes) as it relieves neuropathic pain as well.
重度抑郁症（MDD）是一种复杂的精神疾病，单独出现或伴有其他合并症时，需要对抗抑郁治疗进行不同的调整。一些研究表明，精神活性药物，如5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRIs），比其他常用药物，如5-羟色胺选择性再摄取抑制剂（SSRIs），能发挥更有效、更快的抗抑郁作用，尽管这些差异仍存在争议。在过去五年中，SNRI度洛西汀在治疗MDD、焦虑症和纤维肌痛的临床实践中显示出良好的效果。在本文中，我们通过一项在线自我完成的调查，收集了163位精神科医生关于度洛西汀的使用及其与其他精神科药物比较的信息，涉及精神科医生的知识和经验，以及患者的偏好、症状和幸福感。我们讨论并对比了医生的报告和科学文献，发现了令人满意的一致性，最终得出结论，对于度洛西汀的使用存在共识，这不仅是因为它的耐受性和有效性，还因为它可用于多种情况（如纤维肌痛、糖尿病中的躯体症状），因为它还能缓解神经性疼痛。
